Abstract
Background Prediction of diabetes remission is an important topic in the evaluation of patients with type-2 diabetes (T2D) before bariatric surgery. While several high-quality predictive indices are available, artificial intelligence (AI) algorithms offer the potential for higher predictive capability. The objective was to construct and validate an AI prediction model for diabetes remission after Roux-en-Y gastric bypass surgery.
Methods Patients who underwent surgery from 2007 until 2017 were included in the study, with collection of individual data from the Scandinavian Obesity Surgery Registry (SOReg), the Swedish National Patients Register, the Swedish Prescribed Drugs Register, and Statistics Sweden. A 7-layer convolution neural network (CNN) model was developed using 80% of patients randomly selected from SOReg and 20% of patients for external testing. The predictive capability of the CNN model and currently used scores (DiaRem, Ad-DiaRem, DiaBetter and IMS) were compared.
Results In total, 8057 patients with T2D were included in the study. At 2 years after surgery 77.1% achieved pharmacological remission, while 62.2% achieved complete remission. The area under the receiver operating curve (AUC) for the CNN-model for pharmacological remission was 0.85 [95% confidence interval (CI): 0.83-0.86] during validation, and 0.83 for the final test, which was 9-12% better than the traditional predictive indices. AUC for complete remission was 0.83 (95% CI: 0.81-0.85) during validation, and 0.82 for the final test, which was 9-11% better than the traditional predictive indices.
Conclusion The CNN method had better predictive capability compared to traditional indices for diabetes remission. However, further validation is needed in other countries to evaluate its external generalizability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the regional ethics committee in Stockholm (reference numbers: 2013/535-31/5, 2014/1639-32, and 2017/857-32).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the study are not publicly available because they contain information that could compromise research participant privacy and confidentiality. The authors will make the data available upon reasonable request and with permission of the Committee of Scandinavian Obesity Surgery Registry in Orebro, Sweden.
